Never Use Adhesive Tapes to Seal Sterile Product Containers

Why Adhesive Tapes Have No Place in Sterile Product Sealing

Remember: Never use adhesive tapes to seal sterile product containers — it violates GMP norms and risks contamination.

Why This Matters in GMP

Adhesive tapes, while seemingly harmless, are not suitable for use in sterile pharmaceutical packaging. They can introduce particulate matter, compromise sterile barrier integrity, and contaminate the product through chemical leachables. Sterile drug products require validated container-closure systems that prevent microbial ingress and ensure product stability throughout shelf life. Tapes, which are not sterilizable or particulate-controlled, pose serious risks when used as temporary or supplemental seals.

Inappropriately using adhesive tape during routine operations or to correct minor packaging anomalies reflects poor GMP understanding. For instance, taping a loose flip-off cap or sealing a leak in a container bag can lead to product rejection during visual inspection or even market recall if undetected. Such practices not only create contamination risks but also mask underlying packaging integrity issues that must be properly investigated and resolved. GMP systems demand validated, compliant, and traceable packaging methods — adhesive tape is none of these.

Also Read: Verify Seal Integrity of Finished Product Shippers Before Distribution

Regulatory and Compliance Implications

Per 21 CFR Part 211.94, drug product containers and closures must

not be reactive, additive, or absorptive to the product. Adhesive tapes are not qualified container components and may leach adhesive compounds into the product. The EU Annex 1 further requires aseptic packaging operations to be conducted in controlled environments using approved materials. Using tapes violates these core GMP principles.

Regulators often cite improper packaging materials as critical observations. If tapes are found during visual inspection or retained sample review, this may trigger a full investigation or recall. Moreover, it may reveal systemic weaknesses such as inadequate training, poor deviation management, or uncontrolled corrective actions. WHO GMP guidelines also emphasize that packaging components should be suitable, pre-approved, and free from contamination risk — tape-based sealing fails these checks entirely.

Also Read: Avoid Exposing Finished Products to Ambient Storage Conditions

Implementation Best Practices

Train packaging, production, and warehouse staff to immediately report any damaged or improperly sealed sterile containers. Develop SOPs strictly prohibiting the use of adhesive tapes or makeshift materials in sterile packaging. Clearly define escalation protocols for damaged packaging components, including quarantine procedures and QA notification.

Ensure that all packaging materials, including secondary containers and tamper-evident devices, are qualified for use and validated under normal operating conditions. During deviation investigations, address root causes like equipment failure, improper handling, or supplier issues rather than resorting to unapproved fixes like taping. Encourage a culture of zero tolerance for GMP shortcuts and implement visual inspection procedures to detect foreign materials on packaging surfaces.

Also Read: Do Monitor Compressed Air Points of Use for GMP Purity and Safety

Regulatory References

– 21 CFR Part 211.94 – Drug product containers and closures
– EU GMP Annex 1 – Manufacture of sterile medicinal products
– WHO TRS 986, Annex 2 – Packaging materials and sterile processing
– PIC/S PI 030 – Good Practices for the Inspection of Packaging Activities